Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe page’s displayed revision number has been updated from v3.5.0 to v3.5.3.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. There are no changes to the study content or user-facing information on the page.SummaryDifference0.0%

- Check85 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This appears to be a minor software version update with no visible changes to the study information.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision: v3.4.1 was added (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check93 days agoChange DetectedRevision: v3.4.1 appears on the page, replacing v3.4.0; there are no visible changes to trial content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.